The Enterprise Value as of December 2024 (TTM) for Adaptimmune Therapeutics plc (ADAP) is 58.35M

According to Adaptimmune Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 58.35M. This represents a change of -57.93% compared to the average of 138.70M of the last 4 quarters.

Adaptimmune Therapeutics plc (ADAP) Historical Enterprise Value (quarterly & annually)

How has ADAP Enterprise Value performed in the past?

The mean historical Enterprise Value of Adaptimmune Therapeutics plc over the last ten years is 1.00B. The current 58.35M Enterprise Value has changed 481.07% with respect to the historical average. Over the past ten years (40 quarters), ADAP's Enterprise Value was at its highest in in the September 2018 quarter at 1.28B. The Enterprise Value was at its lowest in in the December 2023 quarter at 61.34M.

Adaptimmune Therapeutics plc (ADAP) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Adaptimmune Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Adaptimmune Therapeutics plc (ADAP) Average Enterprise Value

How has ADAP Enterprise Value performed in the past?

The current Enterprise Value of Adaptimmune Therapeutics plc (ADAP) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Adaptimmune Therapeutics plc (ADAP) Enterprise Value vs. Peers

How is ADAP’s Enterprise Value compared to its peers?

Adaptimmune Therapeutics plc’s Enterprise Value is less than Stoke Therapeutics, Inc. (467.23M), greater than Homology Medicines, Inc. (-103303255.00), less than Black Diamond Therapeutics, Inc. (123.50M), less than Harpoon Therapeutics, Inc. (861.85M), less than Mereo BioPharma Group plc (445.16M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), greater than PDS Biotechnology Corporation (37.39M), greater than Leap Therapeutics, Inc. (48.29M), greater than Affimed N.V. (22.90M), less than Corvus Pharmaceuticals, Inc. (288.04M), greater than Aptose Biosciences Inc. (25.53M), less than Nkarta, Inc. (204.91M), less than Agios Pharmaceuticals, Inc. (1.82B), less than Pliant Therapeutics, Inc. (792.38M), greater than Adicet Bio, Inc. (-13641226.00), greater than MiNK Therapeutics, Inc. (17.71M), less than ImmunoGen, Inc. (8.19B), less than Sangamo Therapeutics, Inc. (487.19M),

Build a custom stock screener for Adaptimmune Therapeutics plc (ADAP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptimmune Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adaptimmune Therapeutics plc (ADAP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adaptimmune Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.